

February 12, 2024

To,

Borosil Limited

1101, Crescenzo, G-Block,
11th Floor, Opp. MCA Club,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400051

Dear Sir(s)/Madam,

The Board of Directors of the Company at their meeting held today i.e. on February 12, 2024, inter alia, considered and approved the following:

I. Un-audited financial results for the quarter and nine months ended December 31, 2023:

The Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023. A copy of the same along with limited review reports of the auditor is attached as annexure -1.

II. Appointment of Mr. C. K. Mishra as an Independent Director:

Appointment of Mr. C. K. Mishra (DIN: 02553126) as an Additional Director designated as an Independent Director on the Board of the Company for a period of five years commencing from February 12, 2024, subject to the approval of the shareholders. Please refer to the attached annexure-2 for further details.

The Board at the aforementioned meeting also noted that the tenure of Mr. Raj Kumar Jain (DIN: 00026544) as an Independent Director of the Company will conclude on April 02, 2024, and therefore he would cease to serve as an Independent Director of the Company w.e.f. close of business hours of April 02, 2024.

The Company has filed the application for listing of its equity shares with the stock exchanges and is currently awaiting their approval. In light of this, we request you to disseminate this information through the stock exchanges.

For Borosil Scientific Limited

Vinayak Patankar
Whole-time Director & CEO
DIN - 07534225

Encl.: as above

Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

**The Board of Directors of
Borosil Scientific Limited
(Formerly Known as Klass Pack Limited)**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Borosil Scientific Limited (Formerly Known as Klass Pack Limited)** ("the Company") for the quarter and nine months ended 31st December, 2023 ("the statement"), attached herewith, prepared in the manner as prescribed in the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulation"), as amended, as the Equity Share Capital of the Company is in the process of Listing with the Stock Exchanges.
2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. **Other Matter**

We draw attention to the Note No. 2 and 7 to the accompanying unaudited standalone financial results regarding accounting of the Scheme from the appointed date 1st April 2022 as approved by the National Company Law Tribunal, Mumbai Bench, though the Scheme has become effective on 2nd December, 2023 and the restatement of comparatives for the previous periods/ year by the management of the Company. Our conclusion is not modified in respect of the above matters.

For Chaturvedi & Shah LLP

Chartered Accountants

Registration No. 101720W/W100355

Anuj Bhatia

Partner

Membership No. 122179

UDIN No. 24122179BKFBFF5228



Place: Mumbai

Date: 12th February, 2024


BOROSIL SCIENTIFIC LIMITED
(FORMERLY KNOWN AS KCLASS PACK LIMITED)
CIN: U74999MH1991PLC061851

Regd. Office : 1101, Crescenzo, G-Block, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(Rs. in lakhs except as stated)

S. No.	Particulars	Standalone					
		Quarter ended			Nine Month Ended		Year Ended
		(31/12/2023)	(30/09/2023)	(31/12/2022)	(31/12/2023)	(31/12/2022)	(31/03/2023)
I. Income:							
Revenue From Operations	8,842.46	8,434.88	8,331.72	25,248.46	23,503.16	32,582.32	
Other Income	134.76	134.79	60.38	373.77	393.26	502.74	
Total Income (I)	8,977.22	8,569.67	8,392.10	25,622.23	23,896.42	33,085.06	
II. Expenses:							
Cost of Materials Consumed	2,950.79	2,663.91	2,778.12	8,400.41	7,890.25	10,723.47	
Purchases of Stock-in-Trade	182.65	160.93	254.22	455.96	951.40	1,239.72	
Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	83.45	8.48	(28.85)	98.50	(818.68)	(1,038.95)	
Employee Benefits Expense	1,524.40	1,599.79	1,443.84	4,697.28	4,345.38	5,834.20	
Finance Costs	33.64	27.25	17.01	90.56	33.79	98.38	
Depreciation and Amortization Expense	411.97	350.24	301.83	1,099.19	849.27	1,165.16	
Other Expenses	2,760.66	2,751.22	2,654.46	8,378.86	7,986.79	10,752.65	
Total Expenses (II)	7,947.56	7,561.81	7,420.63	23,220.76	21,238.20	28,774.63	
III. Profit Before exceptional items and Tax (I - II)	1,029.66	1,007.86	971.47	2,401.47	2,658.22	4,310.43	
IV. Exceptional Items	-	-	-	-	-	-	
V. Profit Before Tax (III - IV)	1,029.66	1,007.86	971.47	2,401.47	2,658.22	4,310.43	
VI. Tax Expense:							
(1) Current Tax	288.95	297.01	332.29	698.62	732.40	1,229.07	
(2) Deferred Tax (Refer Note 5)	(4.35)	(63.59)	(5.91)	(236.32)	33.52	34.40	
Total Tax Expenses	284.60	233.42	326.38	462.30	765.92	1,263.47	
VII. Profit for the Period / Year (V - VI)	745.06	774.43	- 645.09	1,939.17	1,892.30	3,046.96	
VIII. Other Comprehensive Income (OCI)							
Items that will not be reclassified to profit or loss:							
a) Re-measurement gains / (losses) on defined benefit plans	2.16	(4.26)	1.81	(41.73)	5.35	7.70	
b) Income tax effect on above	0.96	1.07	(1.55)	12.01	(2.58)	(2.28)	
Total Other Comprehensive Income	3.12	(3.18)	0.26	(29.72)	2.77	5.42	
IX. Total Comprehensive Income for the Period / Year (VII + VIII)	748.18	771.25	645.35	1,909.45	1,895.07	3,052.38	
X. Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up) (Refer Note 2)	887.96	28.60	28.60	887.96	28.60	28.60	
XI. Share Capital Pending Issuance (Refer Note 4)	-	859.04	857.84	-	857.84	858.11	
XII. Other Equity excluding Revaluation Reserve						33,205.95	
XIII. Earning per equity share (in Rs.) (Face value of Re. 1/- each) (Refer Note 4)							
Basic (Not Annualised)*	0.84 *	0.87 *	0.73 *	2.18 *	2.13 *	3.44	
Diluted (Not Annualised)*	0.84 *	0.87 *	0.73 *	2.18 *	2.13 *	3.44	



BOROSIL SCIENTIFIC LIMITED
(FORMERLY KNOWN AS KLASS PACK LIMITED)

UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(Rs. in lakhs)

S. No.	Particulars	Standalone					
		Quarter ended			Nine Month Ended		Year Ended
		(31/12/2023)	(30/09/2023)	(31/12/2022)	(31/12/2023)	(31/12/2022)	(31/03/2023)
1	Segment Revenue :						
	a. Scientificware	7,121.20	6,955.49	7,344.35	20,744.82	20,322.52	28,554.57
	b. Consumerware	1,721.26	1,479.39	987.37	4,503.64	3,180.64	4,027.75
	Total	8,842.46	8,434.88	8,331.72	25,248.46	23,503.16	32,582.32
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Revenue from operations	8,842.46	8,434.88	8,331.72	25,248.46	23,503.16	32,582.32
2	Segment Results (Profit before tax):						
	a. Scientificware	887.24	948.94	934.30	2,144.89	2,414.36	4,097.45
	b. Consumerware	112.14	72.86	47.02	249.17	151.46	191.80
	Total	999.38	1,021.80	981.32	2,394.06	2,565.82	4,289.25
	Less:- Finance Cost	33.64	27.25	17.01	90.56	33.79	98.38
	Less:- Exceptional Items	-	-	-	-	-	-
	Less:- Other unallocable expenditure (net of income)	(63.92)	(13.31)	(7.16)	(97.97)	(126.19)	(119.56)
	Profit before Tax	1,029.66	1,007.86	971.47	2,401.47	2,658.22	4,310.43
3	Segment Assets						
	a. Scientificware	23,609.10	22,563.44	23,335.87	23,609.10	23,335.87	23,764.00
	b. Consumerware	1,541.79	1,593.89	1,529.40	1,541.79	1,529.40	1,612.52
	c. Un-allocated	20,439.10	19,758.24	17,731.81	20,439.10	17,731.81	17,827.98
	Total	45,589.99	43,915.57	42,597.08	45,589.99	42,597.08	43,204.50
4	Segment Liabilities						
	a. Scientificware	5,522.26	4,763.43	5,601.82	5,522.26	5,601.82	5,064.06
	b. Consumerware	827.64	617.41	723.49	827.64	723.49	312.84
	c. Un-allocated	2,138.44	2,181.25	2,138.13	2,138.44	2,138.13	2,636.65
	Total	8,488.34	7,562.09	8,463.44	8,488.34	8,463.44	8,013.55


Note :

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Company has reported "Segment information", as described below:

Scientificware:- Comprising of manufacturing and trading of items used in Laboratories, Scientific ware, pharmaceutical packaging.


Consumerware:- Comprising of manufacturing and trading items for Domestic use.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.



Notes to the Unaudited Standalone Financial Results for the quarter and nine months ended 31st December, 2023:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the above results.
2. The Hon'ble National Company Law Tribunal, Mumbai Bench ('NCLT') sanctioned the Composite Scheme of Arrangement amongst Borosil Limited ('Demerged Company'), Klass Pack Limited (renamed as 'Borosil Scientific Limited') ('BSL or the Company or Resulting Company or Transferee Company') and Borosil Technologies Limited ('BTL or Transferor Company') and their respective shareholders and creditors ('Scheme'), vide its order dated 2nd November 2023 which inter alia provides for: (a) reduction and reorganization of share capital of the Company ; (b) demerger of Scientific and Industrial Product Business from Borosil Limited into the Company and consequent issue of shares by the Company; and (c) amalgamation of BTL with the Company. The Appointed Date of the Scheme was 1st April 2022. The Scheme became effective from 2nd December 2023. Pursuant to the Scheme, the Company has ceased to be subsidiary company of Borosil Limited, the Demerged Company Further, the Company has allotted 8,59,36,572 fully paid-up equity shares of face value of Re. 1/- each to the shareholders of Demerged Company as on the Record Date (i.e., December 05, 2023), on a proportionate basis. Consequently, the above results have been prepared after giving effect of the Scheme from the appointed date.
3. The Company's equity share capital is in the process of listing on the Stock Exchanges, pending thereof the above results have been prepared in the manner as prescribed in Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
4. Share Capital Pending Issuance for the quarter ended 30th September, 2023, for the quarter and nine months ended 31st December, 2022 and for the year ended 31st March, 2023 represents shares to be issued to the shareholders of the Demerged Company pursuant to the Scheme and accordingly the same has been considered while calculating Earnings Per Share (EPS) as per Indian Accounting Standard (Ind AS) 33 "Earnings Per Share".
5. During the period, the Company has decided to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 and accordingly, the Company has recognised the tax provision for the nine months ended 31st December, 2023 and remeasured the deferred tax assets/liabilities based on the rates prescribed in the said section. The impact of this change has been recognised as tax expense in the current period in the above results.
6. On 27th April, 2023, the Company had acquired 90.17% stake (representing 32,91,330 equity shares) of Goel Scientific Glass Works Limited ("Goel Scientific") from its then majority shareholders. With this acquisition, effective 27th April, 2023, Goel Scientific has become a subsidiary of the Company. Subsequent to this, the Company has acquired an additional 5.31% stake (representing 1,93,570 equity shares), which has resulted into increase in stake of the Company in Goel Scientific from 90.17% to 95.48%.




7. The figures for the previous periods / year have been regrouped / reclassified, wherever necessary. Further, the figures for the previous periods / year have been restated by the management pursuant to the Scheme, to make them comparable.

Place: Mumbai
Date :12th February, 2024



For **Borosil Scientific Limited**


Vinayak Patankar
Whole-time Director & CEO
(DIN 07534225)



Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

**The Board of Directors of
Borosil Scientific Limited
(Formerly Known as Klass Pack Limited)**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Borosil Scientific Limited (Formerly Known as Klass Pack Limited)** ("the Holding Company") and its subsidiary (the holding Company and its subsidiary together refer to as "the Group") for the quarter and nine months ended 31st December, 2023 ("the statement"), attached herewith, prepared by the Holding Company in the manner as prescribed in the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("the Listing Regulation"), as amended, as the Equity Share Capital of the Company is in the process of Listing with the Stock Exchanges.
2. This statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular no. CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

4. The statement includes the results of its subsidiary Goel Scientific Glass Works Limited.
5. Based on our review conducted as above and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial result includes the interim financial information/financial results of 1 subsidiary, whose interim financial information/financial results reflect total revenue of Rs. 1,186.97 Lakhs and Rs. 2,764.35 Lakhs, total net profit/(Loss) after tax of Rs. (167.95) Lakhs and Rs. (501.23) Lakhs and total comprehensive income of Rs. (169.43) Lakhs and Rs. (505.67) Lakhs for the quarter ended 31st December, 2023 and for the period from 1st April, 2023 to 31st December, 2023 respectively, as considered in the unaudited consolidated financial results. The interim financial information/financial results of the above subsidiary has been reviewed by other auditor, whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to amount and disclosures included in respect of that subsidiary is based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement is not modified in respect of the above matter with respect to our reliance on the work done and the report of other auditor.



7. **Other Matter**

We draw attention to the Note No. 2 and 8 to the accompanying unaudited consolidated financial results regarding accounting of the Scheme from the appointed date 1st April 2022 as approved by the National Company Law Tribunal, Mumbai Bench, though the Scheme has become effective on 2nd December, 2023 and the restatement of comparatives for the previous period by the management of the Company. Our conclusion is not modified in respect of the above matters.

For Chaturvedi & Shah LLP

Chartered Accountants

Registration No. 101720WW100355

Anuj Bhatia

Partner

Membership No. 122179

UDIN No. 24122179BKFBFG4787



Place: Mumbai

Date: 12th February, 2024

BOROSIL SCIENTIFIC LIMITED
(FORMERLY KNOWN AS KLASS PACK LIMITED)


CIN: U74999MH1991PLC061851

Regd. Office : 1101, Crescenzo, G-Block, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051
Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(Rs. in lakhs except as stated)

S. No.	Particulars	Quarter ended		Nine Months ended
		(31/12/2023)	(30/09/2023)	(31/12/2023)
I. Income:				
	Revenue From Operations	9,967.86	9,196.86	27,918.99
	Other Income	106.32	144.40	362.19
	Total Income (I)	10,074.18	9,341.26	28,281.18
II. Expenses:				
	Cost of Materials Consumed	3,308.50	3,098.43	9,408.71
	Purchases of Stock-in-Trade	226.43	426.97	765.54
	Changes in Inventories of Work-in-Progress, Finished Goods and Stock-in-Trade	180.67	(363.32)	38.01
	Employee Benefits Expense	1,884.65	2,026.96	5,695.27
	Finance Costs	54.39	73.13	203.37
	Depreciation and Amortization Expense	449.77	385.29	1,199.64
	Other Expenses	3,152.13	3,060.88	9,277.84
	Total Expenses (II)	9,256.54	8,708.34	26,588.38
III. Profit before share of profit in associate, exceptional items and tax (I - II)		817.64	632.92	1,692.80
IV. Share of profit in associates		-	-	-
V. Profit before exceptional items and tax (III + IV)		817.64	632.92	1,692.80
VI. Exceptional items		-	-	-
VII. Profit before tax (V - VI)		817.64	632.92	1,692.80
VIII. Tax Expense :				
	(1) Current Tax	288.95	297.01	698.62
	(2) Deferred Tax (Refer Note 5)	(40.34)	(168.67)	(408.02)
	Total Tax Expenses	248.61	128.34	290.60
IX. Profit for the period (VII - VIII)		569.03	504.58	1,402.20
X. Other Comprehensive Income				
	Items that will not be reclassified to profit or loss:			
	a) Re-measurement gains / (losses) on defined benefit plans	0.18	(8.22)	(47.67)
	b) Income tax on above	1.46	2.07	13.51
	Total Other Comprehensive Income	1.64	(6.15)	(34.16)
XI. Total Comprehensive Income for the period (IX + X)		570.67	498.43	1,368.04
XII. Profit attributable to:				
	Owners of the Company	574.28	514.65	1,426.47
	Non-controlling interest	(5.25)	(10.07)	(24.27)
XIII. Other Comprehensive Income attributable to:				
	Owners of the Company	1.68	(5.99)	(33.96)
	Non-controlling interest	(0.04)	(0.16)	(0.20)
XIV. Total Comprehensive Income attributable to:				
	Owners of the Company	575.96	508.66	1,392.51
	Non-controlling interest	(5.29)	(10.23)	(24.47)
XV. Paid up Equity Share Capital (Face value of Re. 1/- each fully paid up) (Refer Note 2)		887.96	28.60	887.96
XVI. Share Capital Pending Issuance (Refer Note 4)		-	859.04	-
XVII. Other Equity excluding revaluation reserve				
XVIII. Earning per Equity Share (in Rs.) (Face value of Re. 1/- each) (Refer Note 4)				
	Basic (Not Annualised)*	0.65 *	0.58 *	1.61 *
	Diluted (Not Annualised)*	0.65 *	0.58 *	1.61 *



BOROSIL SCIENTIFIC LIMITED
(FORMERLY KNOWN AS KLASS PACK LIMITED)

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

(Rs. in lakhs except as stated)

S. No.	Particulars	Quarter ended		Nine Months ended
		(31/12/2023)	(30/09/2023)	(31/12/2023)
1	Segment Revenue :			
	a. Scientificware	8,246.60	7,717.47	23,415.35
	b. Consumerware	1,721.26	1,479.39	4,503.64
	Total	9,967.86	9,196.86	27,918.99
	Less : Inter Segment Revenue	-	-	-
	Revenue from operations	9,967.86	9,196.86	27,918.99
2	Segment Results (Profit before tax and non-controlling interests):			
	a. Scientificware	689.11	604.43	1,544.18
	b. Consumerware	112.14	72.86	249.17
	Total	801.25	677.29	1,793.35
	Less:- Finance cost	54.39	73.13	203.37
	Less:- Exceptional item	-	-	-
	Less:- Other unallocable expenditure (net of income)	(70.78)	(28.76)	(102.82)
	Profit before Tax	817.64	632.92	1,692.80
3	Segment Assets			
	a. Scientificware	28,606.40	27,477.94	28,606.40
	b. Consumerware	1,541.79	1,593.89	1,541.79
	c. Un-allocated	17,477.86	17,419.11	17,477.86
	Total	47,626.05	46,490.94	47,626.05
4	Segment Liabilities			
	a. Scientificware	7,227.61	6,602.46	7,227.61
	b. Consumerware	827.64	617.41	827.64
	c. Un-allocated	2,910.91	3,168.72	2,910.91
	Total	10,966.16	10,388.59	10,966.16


Note :

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Company has reported "Segment information", as described below:

Scientificware:- Comprising of manufacturing and trading of items used in Laboratories, Scientific ware, pharmaceutical packaging and process system.


Consumerware:- Comprising of manufacturing and trading of items for Domestic use.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.



Notes to the Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2023:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the above results.
2. The Hon'ble National Company Law Tribunal, Mumbai Bench ('NCLT') sanctioned the Composite Scheme of Arrangement amongst Borosil Limited ('Demerged Company'), Klass Pack Limited (renamed as 'Borosil Scientific Limited') ('BSL or the Company or Resulting Company or Transferee Company') and Borosil Technologies Limited ('BTL or Transferor Company') and their respective shareholders and creditors ('Scheme'), vide its order dated 2nd November 2023 which inter alia provides for: (a) reduction and reorganization of share capital of the Company ; (b) demerger of Scientific and Industrial Product Business from Borosil Limited into the Company and consequent issue of shares by the Company; and (c) amalgamation of BTL with the Company. The Appointed Date of the Scheme was 1st April 2022. The Scheme became effective from 2nd December 2023. Pursuant to the Scheme, the Company has ceased to be subsidiary company of Borosil Limited, the Demerged Company Further, the Company has allotted 8,59,36,572 fully paid-up equity shares of face value of Re. 1/- each to the shareholders of Demerged Company as on the Record Date (i.e., December 05, 2023), on a proportionate basis. Consequently, the above results have been prepared after giving effect of the Scheme from the appointed date.
3. The Company's equity share capital is in the process of listing on the Stock Exchanges, pending thereof the above results have been prepared in the manner as prescribed in Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
4. Share Capital Pending Issuance for the quarter ended 30th September, 2023 represents shares to be issued to the shareholders of the Demerged Company pursuant to the Scheme and accordingly the same has been considered while calculating Earnings Per Share (EPS) as per Indian Accounting Standard (Ind AS) 33 "Earnings Per Share".
5. During the period, the Company has decided to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019 and accordingly, the Company has recognised the tax provision for the nine months ended 31st December, 2023 and remeasured the deferred tax assets/liabilities based on the rates prescribed in the said section. The impact of this change has been recognised as tax expense in the current period in the above results.
6. On 27th April, 2023, the Company had acquired 90.17% stake (representing 32,91,330 equity shares) of Goel Scientific Glass Works Limited ("Goel Scientific") from its then majority shareholders. With this acquisition, effective 27th April, 2023, Goel Scientific has become a subsidiary of the Company. Subsequent to this, the Company has acquired an additional 5.31% stake (representing 1,93,570 equity shares), which has resulted into increase in stake of the Company in Goel Scientific from 90.17% to 95.48%.




7. As the Company did not have any subsidiary company till 31st March, 2023, the Company had started preparing the consolidated financial results since the quarter ended 30th June, 2023 and accordingly, figures for the corresponding previous periods/year have not been given in respect of aforesaid consolidated financial results.
8. The figures for the previous periods have been regrouped / reclassified, wherever necessary. Further, the figures for the previous periods have been restated by the management pursuant to the Scheme, to make them comparable.

Place: Mumbai
Date :12th February, 2024

For Borosil Scientific Limited


Vinayak Patankar
Whole-time Director & CEO
(DIN 07534225)



Mr. C.K. Mishra has been a Civil Servant belonging to the Indian Administrative Service. He joined the Service (IAS) in 1983 and superannuated as Secretary in the Ministry of Environment, Forest and Climate Change, Government of India. He has been spearheading the Indian efforts at addressing climate change issues and at policy interventions in matter relating to pollution and air quality. He led India's negotiations at important forums such as United Nations Framework Convention on Climate Change (Conference of the Parties (COP)) to assess progress in dealing with climate change; Montreal Protocol on Substances that Deplete the Ozone Layer and various other multilateral events. He was also the administrative head of Forest & Wildlife conservation efforts in India where India saw continuous increase in forest cover. His interventions and policy initiatives have brought India in the category of very few countries in the world on course to achieve the 2 degree target of global warming.

Prior to this, he was Secretary in the Ministry of Health & Family Welfare and also held the additional charge of Ministry of AYUSH for some time. As Additional Secretary & Mission Director, National Health Mission, he led one of the largest public health programmes globally. In about 37 years of public service, he has served as an administrator, policy-maker and public health strategist holding a wide range of assignments in the fields of health, education, industry and power.

At the state level, he held important Leadership positions like Secretary Health; Secretary Power; Industry and several other assignments. At the Central level, he has worked in the Ministries of Textiles, Defence, MSME, apart from Health and Environment. He is globally recognised for his significant contributions to improving the Indian Public Health landscape.

He has been the leader in implementing 'Mission Indradhanush' – the largest ever focussed campaign to immunize children. His views on Maternal child health are well accepted globally as he brings a practical implementation perspective to his views. His proactive policy changes helped India see a huge reduction in maternal and child mortality, positive intervention in non-communicable diseases, including, the national dialysis programme. He held leadership positions as head of many international organizations relating to maternal child health (PMNCH), tobacco control (FCTC), population stabilization etc.

Born in Patna, Bihar, C.K. Mishra earned his Bachelor's Degree in History (Hons.) from St. Stephens College, Delhi University. In addition to this, he has received a Post Graduate Diploma in Media Law at NALSAR, Hyderabad. He has also completed the Advanced Leadership Programme from Australia and New Zealand School of Government (ANZSOG), Australia.

Mr. C. K. Mishra is not related to any of the Directors of the Company.

Further Mr. C. K. Mishra has confirmed that he is not debarred from holding the office of Director by virtue of any order of SEBI or any other authority.